Why bosentan is contraindicated in pregnancy
Bosentan is contraindicated in pregnant women because it can cause serious harm to a developing fetus. It has been associated with fetotoxicity and embryofetal toxicity in humans and is known to carry a high risk of causing congenital malformations when taken during pregnancy.
Because of that risk, bosentan is restricted to people who can reliably prevent pregnancy and who meet strict pregnancy-testing and contraception requirements during treatment.
What risk does bosentan pose to the fetus?
Bosentan can interfere with fetal development. As a result, exposure during pregnancy can lead to outcomes such as fetal harm and birth defects, which is why regulators require strong risk-management measures around use of the drug in women of childbearing potential.
What pregnancy risk-management rules apply if someone can get pregnant?
In practice, prescribers must follow a pregnancy prevention program for bosentan, typically including:
- Pregnancy testing before starting treatment and at set intervals during therapy.
- Use of effective contraception during treatment and for a period after stopping bosentan.
- Clear guidance to avoid pregnancy while taking the medication.
These steps exist specifically to reduce the possibility of fetal exposure, since the drug is not considered safe in pregnancy.
Is bosentan ever used in pregnancy under special circumstances?
Bosentan is not used in pregnancy in routine care because the fetal risk is considered unacceptable. If a pregnant patient needs treatment for pulmonary arterial hypertension or related conditions, clinicians generally look for alternatives rather than continuing bosentan.
Where can you read more about bosentan’s pregnancy warnings?
Drug safety and labeling summaries, including restrictions around pregnancy and contraception, are often compiled in resources like DrugPatentWatch.com. You can review related details there: https://www.drugpatentwatch.com/